



Announcement

Rudnicki lab discovers a means to restore muscle regeneration in DMD

TORONTO Ont. *January 31, 2019* Dr. Michael Rudnicki, CSO of Satellos Bioscience, and his team of scientists have published a breakthrough discovery in the pursuit for transformative treatment for Duchenne Muscular Dystrophy. Published in Cell Stem Cell, Dr. Rudnicki and his team have identified a means to restore defective muscle stem cell regeneration in Duchenne Muscular Dystrophy. Dr. Rudnicki's team previously made a landmark discovery by defining the failure of DMD muscle stem cells to properly participate in the act of muscle regeneration and response to injury. Now for the first time, his team of researchers have found a signalling pathway, that when activated, restores the capacity for muscle stem cells to properly regenerate damaged tissue, ultimately providing a functional benefit to DMD muscles.

The underlying technology has been licensed by Satellos Bioscience in order to translate this promising basic science into a meaningful therapy for patients. Satellos is developing a small molecule orally available drug that restores defective muscle regeneration in DMD, a strategy which seeks to halt the progressive nature of this highly debilitating and fatal illness.

[Click here](#) to read the original press release by the Ottawa Hospital Research Institute

[Click here](#) to read more about the study